Funding Programme for COVID-19 Medicines

On 19 May 2021 the Federal Council approved a funding programme to support the research, development and manufacture of COVID-19 medicines. The call for applications closed on 16 August 2021.

The framework conditions of the funding programme approved by the Federal Council are as follows:

• The funded projects contribute to the secure and rapid provision of COVID-19 medicines for Switzerland, with medicines very likely to be available to the Swiss population by the end of 2022.
• The projects have a high level of potential for clinical innovation.
• The subsidiarity and necessity of the support must be guaranteed.
• The development plan must be robust and of high scientific quality.
• Applicants must demonstrate relevant expertise in pharmaceutical development projects and present a convincing business plan.
• The federal government must obtain pre-defined considerations in return (in particular a purchase option/right of first refusal).
• Applications should be assessed in a transparent and equitable manner.

Evaluation of applications

During its session on 30 June 2021, the Federal Council mandated Innosuisse and us to implement the funding programme jointly. The call for applications started on 19 July and closed on 16 August 2021, 12 pm (CEST, midday).

The funding applications received are currently being evaluated by experts commissioned by Innosuisse and by the FOPH. On the basis of these evaluations, the FOPH will decide on the possible award of financial support before the end of October 2021.

Further information about the call for applications is available on the Innosuisse website.

Last modification 10.08.2021

Top of page


Federal Office of Public Health FOPH
Project Team «Funding programme for COVID-19 medicines»
Schwarzenburgstrasse 157
3003 Berne

Print contact